Navigation Links
Sensitech to Sponsor Panel Session at IQPC Cool Chain Europe 2008
Date:1/9/2008

SASSENHEIM, Netherlands, Jan. 9 /PRNewswire/ -- Sensitech, the global leader in cold chain visibility solutions, will sponsor "Cool Chain Integrity and Visibility - A Discussion and Review of Industry Implementation Trends and Expectations for Return on Investment" at IQPC (International Quality & Productivity Center) Cool Chain Europe 2008, Brussels, Belgium. Sensitech is a wholly owned subsidiary of Carrier Corp., a unit of United Technologies Corp. (NYSE: UTX).

(Logo: http://www.newscom.com/cgi-bin/prnh/20050209/NEW018LOGO )

Held Jan. 28-30, Cool Chain Europe is the largest, most comprehensive event of its kind. More than 200 professionals from manufacturing, distribution, quality assurance, packaging and supply chain management, as well as service providers, will discuss best practices. The focus of this year's conference is "Meeting global challenges to ensure a safe and compliant supply of bio-pharmaceutical products and clinical supplies."

Sensitech strategic marketing director Henry Ames will lead a roundtable discussion on Jan. 29. He will also participate in a Jan. 30 panel discussion titled: "Explore Industry Best Practices for Storage, Handling and Distribution of Temperature-Sensitive Goods Across a Complex Global Supply Chain." This panel will be moderated by Rafik H. Bishara Ph.D.
Other panelists include:

-- Laurent Boer, vice president, Global Supply Chain, UCB Pharma

-- Jim Bacon, director, Global Demand Planning and Customer Operations,

Talecris Biotherapeutics

-- Jeff Sitzler, manager, Business Development, FedEx Custom Critical, and

-- Derrik Lenzer, department manager, Sh
'/>"/>

SOURCE Sensitech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
3. Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results
4. Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Human Genome Sciences to Sponsor Conference Call
7. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
8. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
9. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
10. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
11. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... Enhances ... Senior Management Team, ROCKVILLE, Md., June 18 EntreMed, ... the treatment of cancer and inflammatory diseases, today,announced the appointment ... and Business Development. Mr. Bliss has been elected,an executive officer ...
... Access to data may provide potential for label expansion ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) announced today ... Bayer,s phase III Zevalin(R) ([90Y]-ibritumomab,tiuxetan) First-line Indolent Trial, FIT ... be appropriate for CTI to begin discussions with the,U.S. ...
... IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... guidance for full year 2008,revenue to be in the ... year,2008 earnings per adjusted pro-forma fully diluted share (excluding ... IPO) to be in the,range of $0.87 to $0.94. ...
Cached Biology Technology:EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 2EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 3EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 2CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 3CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 4CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 5CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application 6IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Researchers from the Institute of Food Research and The ... a gut bacterium, to help understand how these organisms ... relationship between gut bacteria and the gastrointestinal tract is ... the role of bacteria in establishing and maintaining gut ...
... , Higher temperatures could significantly impact California and other ... next 30 years, according to a new study led ... June 30 edition of Environmental Research Letters , ... land suitable for cultivating premium wine grapes in high-value ...
... BALTIMORE, June 29, 2011 BD Biosciences, a ... today the availability of BD Recharge™, a chemically ... manufacturing that offers productivity comparable to yeast-based peptones. ... significant advance for biopharmaceutical cell culture," said Robert ...
Cached Biology News:Genome analysis will reveal how bacteria in our guts make themselves at home 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2
For microscopy...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Biology Products: